Opendata, web and dolomites

ImmuneHunter SIGNED

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Total Cost €


EC-Contrib. €






 ImmuneHunter project word cloud

Explore the words cloud of the ImmuneHunter project. It provides you a very rough idea of what is the project "ImmuneHunter" about.

data    distinguish    characterization    disease    status    limited    routine    discover    simultaneously    variation    contribution    detect    capacity    capability    huge    empower    sophisticated    unprecedented    contracts    pilot    analyzing    amounts    superior    revenues    tool    restricted    grows    technologies    annual    diagnose    breaking    spending    nearly    full    discovery    million    tests    immune    market    diagnostics    2020    throughput    diagnostic    therapeutics    premature    deaths    signatures    radically    additional    causes    illness    handle    antibody    analysed    frequent    healthcare    diseases    vaccines    service    scalability    accurately    25    repertoire    biotech    applies    healthy    molecular    six    advantage    ageing    times    discovered    mva    mind    accuracy    ground    companies    heart    format    2018    signed    profiling    cancer    overview    services    clinical    least    mimotope    demand    entry    platforms    bioinformatics    patient    competing    73    half    unable    corresponding    resolution    platform    reduce    analytical    biomarkers    chronic    applicable    death    health    establishing    figure    multiplexed    small    protobios    ict   

Project "ImmuneHunter" data sheet

The following table provides information about the project.


Organization address
address: MAEALUSE 4
postcode: 12618
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Estonia [EE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTOBIOS OU EE (TALLINN) coordinator 50˙000.00


 Project objective

Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status.

Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool.

We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018.

The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNEHUNTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNEHUNTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)


CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More